Brought to you by 
Biohaven nets $303mm through FOPO
12 Aug 2019
Executive Summary
Neuro-focused Biohaven Pharmaceutical Holding Co. Ltd. netted $303mm in a public offering of 7.5mm shares (including partial exercise of the overallotment) at $43. The company will use the proceeds to support continued and expanded development of its three platforms: calcitonin gene-related peptide (CGRP) receptor antagonists; glutamate modulators; and myeloperoxidase (MPO) inhibitors. An NDA submission is expected in mid-2019 for its most advanced CGRP candidate rimegepant (in Phase III for migraine) using a priority review voucher (PRV) Biohaven bought earlier this year from GW Pharmaceuticals, allowing the former to designate a single NDA for priority status and providing an accelerated six-month review period.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biohaven nets $303mm through FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice